Suppr超能文献

移植其他器官和组织后的患者经活检诊断的肾脏疾病。

Biopsy-diagnosed renal disease in patients after transplantation of other organs and tissues.

机构信息

Department of Nephrology and Hypertension, Hannover Medical School, Integriertes Forschungs- und Behandlungszentrum (IFB-Tx), Germany.

出版信息

Am J Transplant. 2010 Sep;10(9):2017-25. doi: 10.1111/j.1600-6143.2010.03224.x.

Abstract

Renal function deteriorates in about half of patients undergoing other transplants. We report the results of 105 renal biopsies from 101 nonrenal transplant recipients (bone marrow 14, liver 41, lung 30, heart 20). Biopsy indications were protracted acute renal failure (9%), creatinine increases (83%), heavy proteinuria (22%), or renal insufficiency before re-transplantation (9%). Histological findings other than nonspecific chronic changes, hypertension-related damage, and signs of chronic CNI toxicity included primary glomerular disease (17%), mostly after liver transplantation (21%) or after bone marrow transplantation (29%), and thrombotic microangiopathy (TMA) namely (10%). TMA had the most serious impact on the clinical course. Besides severe hypertension, one TMA patient died of cerebral hemorrhage, 5 had hemolytic-uremic syndrome, and 6 rapidly developed end-stage renal failure. TMA patients had the shortest kidney survival post-biopsy and, together with patients with acute tubular injury, the shortest kidney and patient survival since transplantation. Nine TMA patients had received CNI, 3 of them concomitantly received an mTOR-inhibitor. CNI toxicity is implicated in most patients with renal failure after transplant of other organs and may play a role in the development of TMA, the most serious complication. However, decreased renal function should not be routinely ascribed to CNI.

摘要

肾功能在大约一半接受其他移植的患者中恶化。我们报告了 101 名非肾移植受者(骨髓 14 例、肝脏 41 例、肺 30 例、心脏 20 例)的 105 例肾活检结果。活检指征为迁延性急性肾衰竭(9%)、肌酐升高(83%)、大量蛋白尿(22%)或再移植前肾功能不全(9%)。除非特异性慢性改变、高血压相关损伤和慢性 CNI 毒性迹象外,组织学发现还包括原发性肾小球疾病(17%),主要发生在肝移植(21%)或骨髓移植(29%)后,以及血栓性微血管病(TMA)(10%)。TMA 对临床病程的影响最严重。除严重高血压外,1 例 TMA 患者死于脑出血,5 例患者发生溶血尿毒综合征,6 例患者迅速发展为终末期肾衰竭。TMA 患者的活检后肾脏存活率最短,与急性肾小管损伤患者一起,移植后肾脏和患者的存活率最短。9 例 TMA 患者接受了 CNI 治疗,其中 3 例同时接受了 mTOR 抑制剂治疗。CNI 毒性与其他器官移植后肾功能衰竭的大多数患者有关,并且可能在 TMA(最严重的并发症)的发展中发挥作用。然而,肾功能的下降不应常规归因于 CNI。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验